Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Lieverse RIY, Van Limbergen EJ, Oberije CJG, Troost EGC, Hadrup SR, Dingemans AC, Hendriks LEL, Eckert F, Hiley C, Dooms C, Lievens Y, de Jong MC, Bussink J, Geets X, Valentini V, Elia G, Neri D, Billiet C, Abdollahi A, Pasquier D, Boisselier P, Yaromina A, De Ruysscher D, Dubois LJ, Lambin P. Lieverse RIY, et al. Among authors: lievens y. BMC Cancer. 2020 Jun 15;20(1):557. doi: 10.1186/s12885-020-07055-1. BMC Cancer. 2020. PMID: 32539805 Free PMC article.
Brachytherapy with iridium-192 for bladder cancer.
Van Poppel H, Lievens Y, Van Limbergen E, Baert L. Van Poppel H, et al. Among authors: lievens y. Eur Urol. 2000 May;37(5):605-8. doi: 10.1159/000020200. Eur Urol. 2000. PMID: 10765101
Dose-intensified accelerated vindesine-ifosfamide-cisplatin (VIP) chemotherapy followed by high-dose accelerated hyperfractionated radiotherapy in patients with pathologically proven stage IIIB non-small cell lung cancer: a feasibility study.
De Ruysscher D, Lievens Y, Van den Brande P, Nackaerts K, Vansteenkiste J. De Ruysscher D, et al. Among authors: lievens y. Radiother Oncol. 2002 Jul;64(1):33-6. doi: 10.1016/s0167-8140(02)00144-5. Radiother Oncol. 2002. PMID: 12208572
Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience.
Lorent N, De Leyn P, Lievens Y, Verbeken E, Nackaerts K, Dooms C, Van Raemdonck D, Anrys B, Vansteenkiste J; Leuven Lung Cancer Group. Lorent N, et al. Among authors: lievens y. Ann Oncol. 2004 Nov;15(11):1645-53. doi: 10.1093/annonc/mdh435. Ann Oncol. 2004. PMID: 15520066 Free article. Clinical Trial.
Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy.
Dehing-Oberije C, Yu S, De Ruysscher D, Meersschout S, Van Beek K, Lievens Y, Van Meerbeeck J, De Neve W, Rao B, van der Weide H, Lambin P. Dehing-Oberije C, et al. Among authors: lievens y. Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):355-62. doi: 10.1016/j.ijrobp.2008.08.052. Epub 2008 Dec 25. Int J Radiat Oncol Biol Phys. 2009. PMID: 19095367
A systematic methodology review of phase I radiation dose escalation trials.
Pijls-Johannesma M, van Mastrigt G, Hahn SM, De Ruysscher D, Baumert BG, Lammering G, Buijsen J, Bentzen SM, Lievens Y, Kramar A, Lambin P. Pijls-Johannesma M, et al. Among authors: lievens y. Radiother Oncol. 2010 May;95(2):135-41. doi: 10.1016/j.radonc.2010.02.009. Epub 2010 Mar 24. Radiother Oncol. 2010. PMID: 20338652
Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients.
Nalbantov G, Kietselaer B, Vandecasteele K, Oberije C, Berbee M, Troost E, Dingemans AM, van Baardwijk A, Smits K, Dekker A, Bussink J, De Ruysscher D, Lievens Y, Lambin P. Nalbantov G, et al. Among authors: lievens y. Radiother Oncol. 2013 Oct;109(1):100-6. doi: 10.1016/j.radonc.2013.08.035. Epub 2013 Sep 14. Radiother Oncol. 2013. PMID: 24044794 Free article.
202 results